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Post-translational modiﬁcation of substrate proteins by small ubiquitin-like modiﬁer (SUMO) regulates a
vast array of cellular processes. SUMOylation occurs through three sequential enzymatic steps termed E1,
E2 and E3. Substrate selection can be determined through interactions between the target protein and
the SUMO E2 conjugating enzyme Ubc9 and speciﬁcity can be enhanced by substrate interactions with
E3 ligase enzymes. We used the putative substrate recognition (PINIT) domain from the SUMO E3 PIAS3
as bait to identify potential SUMO substrates. One protein identiﬁed was Argonaute-2 (Ago2), which
mediates RNA-induced gene silencing through binding small RNAs and promoting degradation of
complimentary target mRNAs. We show that Ago2 can be SUMOylated in mammalian cells by both
SUMO1 and SUMO2. SUMOylation occurs primarily at K402, and mutation of the SUMO consensus site
surrounding this lysine reduces Ago2-mediated siRNA-induced silencing in a luciferase-based reporter
assay. These results identify SUMOylation as a potential regulator of Ago2 activity and open new avenues
for research into the mechanisms underlying the regulation of RNA-induced gene silencing.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Small RNA-mediated regulation of gene expression is a funda-
mental control mechanism in eukaryotic cells. RNA-induced gene
silencing reduces translation of target mRNAs and is primarily
mediated by members of the Argonaute (Ago) family of RNA-
binding proteins [1]. There are 4 Ago proteins in humans (Ago1-
4), which control RNA-induced gene silencing through binding to
mRNAs complimentary to their bound RNA. Three types of RNA e
microRNA (miRNA), short interfering RNA (siRNA) or PIWI-
associated RNA (piRNA) e can bind to Ago family proteins [1] and
silencing can occur through promoting degradation of the target
transcript, inhibition of translation or, in the case of Ago2 in
humans, by directly cleaving the target mRNA [2].
miRNAs are initially synthesised by RNA polymerase III and
cropped in the nucleus by a processing complex consisting of the
RNAse III family member Drosha and DCGR8. After processing,
miRNAs are exported to the cytosol through the action of Exportin-
5 and RanGTP, where they are further processed by Dicer and
loaded onto Ago. This miRNA-loaded Ago is termed the RNA-
induced silencing complex (RISC), and is the core effector of RNA
interference (RNAi) [1].
Because of their critical role in the regulation of RNA stability. Wilkinson).
r Inc. This is an open access articland protein synthesis, Ago proteins are subject to multiple post-
translational modiﬁcations (PTMs) to ﬁne-tune their function [3].
The ﬁrst reported PTM of Ago2 was prolyl 4-hydroxylation at pro-
line 700, which increases Ago2 stability and miRNA activity during
hypoxia [4,5]. Also, hypoxia-induced phosphorylation of Y393 by
EGFR reduces Ago2 association with Dicer, to promote cell survival
[6]. Phosphorylation of serine 387 in Ago2 by MAPK or Akt3 reg-
ulates its localisation to cytoplasmic foci (P-bodies) enriched in RNA
processing machinery [7,8]. Furthermore, Ago2 ubiquitination
regulates Ago2 turnover in activated T cells [9], while poly-ADP-
ribosylation under conditions of stress recruits Ago proteins to
stress granules, resulting in inhibition of their miRNA activity [10].
SUMOylation is a reversible PTM of lysine residues in substrate
proteins by attachment of small ubiquitin-like modiﬁer (SUMO) [11].
In mammals, there are three SUMO paralogues, SUMO1-3, which are
conjugated to target proteins via an enzymatic pathway analogous to
the ubiquitin pathway. In the nearly 20 years since its discovery,
several hundred SUMO substrates have been identiﬁed which
participate in nearly every cellular process. SUMOylation is particu-
larly well-characterised for its role in the nucleus where it plays
diverse roles in transcription, nuclear organisation and DNA repair
[12]. Furthermore, it is becoming increasingly clear that SUMO also
plays critical roles outside the nucleus, including atmitochondria and
the cell surface [13,14].
In order to be conjugated to target proteins, SUMO is ﬁrst acti-
vated in an ATP-dependent manner by an E1 complex, ae under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the active site cysteine of the single SUMO conjugating enzyme,
Ubc9, via a thioester bond. Ubc9 then, in conjunction with a
number of known E3 enzymes, which enhance the rate and spec-
iﬁcity of modiﬁcation, transfers SUMO to the target lysine in the
substrate via an isopeptide bond [11]. Importantly, SUMOylation is
a reversible modiﬁcation, and can be removed from substrates via
the action of SUMO proteases, of which the SENP family are the best
characterised [15].
The ﬁrst proteins identiﬁed that possess E3 ligase activity to-
wards SUMO were the PIAS family, which consists of 4 members,
PIAS1, PIASx, PIAS3 and PIASy [16]. Each member has been shown
to enhance the transfer of SUMO from thioester-loaded Ubc9 to a
wide range of target proteins. The core E3 activities of the PIAS
proteins require their SP-RING domains, zinc binding domains
similar to those found in ubiquitin ligases of the RING-type E3
family.
By bringing together Ubc9, bound at the SP-RING domain, and
SUMO, bound at the C-terminal domain, PIAS proteins enhance
SUMO transfer by positioning the Ubc9 ~ SUMO thioester optimally
for substrate conjugation. In this scenario, Ubc9 primarily deﬁnes
substrate speciﬁcity, since it directly binds the SUMO consensus
motif, jKE, where j is a large hydrophobic residue [17]. However,
for some substrates, such as the DNA sliding clamp PCNA [18,19],
direct binding of the PIAS protein to the substrate is required for
efﬁcient SUMO transfer. In these cases, a conserved domain found
in all of the PIAS proteins, the PINIT domain, has been implicated in
substrate binding [18,19].
Here, using a mass spectrometry approach, we have identiﬁed
Ago2 as an interactor of the PINIT domain of the SUMO E3 ligase
PIAS3. Furthermore, we demonstrate that Ago2 can be SUMOylated
in mammalian cells, primarily at K402, and that ablation of Ago2
SUMOylation negatively inﬂuences its RNAi activity. Together with
another very recent report of Ago2 SUMOylation [20], these data
provide new insight into the regulation of Ago2 function.
2. Materials and methods
2.1. Plasmid constructs
Human myc-tagged Ago2 and the ﬁreﬂy and renilla luciferase
constructs were a gift from Dr Anna Antoniou (University of Bristol,
UK). YFP-SUMO1 constructs were a gift from Prof. Frauke Melchior
(ZMBH, Heidelberg, Germany). FLAG-Ubc9, and YFP-SUMO-2 con-
structs have been described previously [21].
2.2. Cell culture, transfection and lysis
Cell lines were cultured as described previously [22]. Ago2
knockout MEFs were kindly provided by Prof. Gregory Hannon
(Cold Spring Harbour Laboratory, USA). For transfection of N2a cells
or MEF cells, TransIT reagent (Mirus) or Lipofectamine 2000 (Invi-
trogen) were used, according to the manufacturers instructions.
48 h post-transfection, cells were lysed in 25 mM HEPES (pH 7.5),
150 mM NaCl, 1% Triton-X-100, 0.1% SDS and complete protease
inhibitors (Roche). Cleared lysates were produced by centrifugation
at 16,000 g for 20 min. For SUMOylation assays, cells were lysed in
lysis buffer containing 20mMNEM (N-Ethylmaleimide) to preserve
SUMOylation. Rat brain lysate was prepared as described previ-
ously [22].
2.3. GST-pulldowns
GST-fusion proteins were prepared as described previously [22].
GST fusion proteins were immobilised on glutathione sepharosebeads (GE Healthcare), washed 3 times with 500 ml HTG wash
buffer (10 mM HEPES, 150 mM NaCl, 10% glycerol, 0.05% Triton X-
100, 4 mM DTT, pH 7.5) and incubated with mammalian cell lysates
(0.25e1mg total protein) on awheel at 4 C for 1 h. Afterwards they
were washed 3 times with 6His buffer (10 mM HEPES, 150 mM
NaCl, pH 7.5) containing 0.005% Triton-X100. Proteins were eluted
in Laemmli buffer, and the mixture boiled at 95 C for 10 min. For
mass spectrometry boiled samples were run on a 4e20% gradient
gel (Pierce) and stained with Coomassie.
2.4. GFP-trap pulldowns
SUMO-1 and -2 tagged N-terminally with YFP were co-
expressed with FLAG-Ubc9 and myc-Ago2 (1 mg of each for a
35 mm dish) for SUMOylation assays in N2a cells. Co-
immunoprecipitations to pull-down YFP-tagged proteins were
performed using GFP-trap beads (Chromotek) as described previ-
ously [21]. Final washes were carried out in 6His buffer plus 0.5%
Triton-X100.
2.5. Mass spectrometry
Mass spectrometry was performed by Dr. Kate Heesom at the
School of Biochemistry Proteomics Facility at the University of
Bristol. Protein bands were cut into 1mm2 pieces and digestedwith
sequencing grade trypsin (Promega) using a ProGest automated
digestion unit (Digilab Ltd.). The resulting peptides were analysed
by mass spectrometry. Mass spectra were recorded in positive ion
reﬂector mode on an Applied Biosystems 4700 MALDI mass spec-
trometer. Data was analyzed using the MASCOT 1.9 search engine
(Matrix Science) to search against the appropriate NCBI species
protein database. Search parameters allowed for one missed tryptic
cleavage site, the carbamidomethylation of cysteine, and the
possible oxidation of methionine; precursor ionmass tolerancewas
100 ppm and fragment ion mass tolerance was 0.25 Da. All iden-
tiﬁed proteins have a Mascot score greater than 95% (the default
MASCOT threshold for such searches), corresponding to a statisti-
cally signiﬁcant (p < 0.05) identiﬁcation.
2.6. Western blotting
Western blotting was performed as described previously [22]).
Antibodies used were: anti-myc-tag (Cell Signalling Technology
2276 (9B11)), anti-Ago2 (Cell Signalling Technology, #2897
(C34C6)), anti-GFP (Santa Cruz Biotech. sc-8334), anti-actin (Sig-
maeAldrich A5441). HRP-conjugated secondary antibodies were
obtained from Sigma.
2.7. Ago2 functional assays
Ago2 null MEFs were co-transfected with 1 mg of myc-tagged
WT hAgo2, or its mutants (K402R or 3mutCS) or GFP, 0.2 mg of
Renilla luciferase (RL), 0.2 mg of Fireﬂy luciferase (FL) and 30 pmoles
of siRNA against RL or a scrambled siRNA, using Lipofectamine
2000. Cells were lysed and the reporter activities from RL and FL
were measured using the Dual-Luciferase Reporter Assay System
(Promega) and a Fluoroskan Ascent FL microplate ﬂuorometer and
luminometer equipped with dispensers (Thermo Fisher Scientiﬁc).
RL signal was then normalised to FL signal.
2.8. Statistical analysis
All quantiﬁed results shown are the mean ± SEM. Statistical
analyses were performed using GraphPad Prism. Differences be-
tween data sets were assessed by one-way ANOVA with
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3.1. Ago2 interacts with the PINIT domain of PIAS3
To identify putative SUMO target proteins, we fused the PINIT
domain of the SUMO E3 ligase PIAS3 to GST (Fig. 1A). After puriﬁ-
cation of GST-PINIT from bacteria we used this fusion protein as a
bait to pulldown interacting proteins from both COS-7 cell lysate
and whole rat brain homogenate and subjected the captured pro-
teins to mass spectrometry analysis.
Several putative PIAS3-PINIT interacting proteins, including the
presynaptic active zone proteins CAST1 and CAST2 and the
neuronal type III intermediate ﬁlament protein peripherin (data not
shown) were detected from brain lysate. Interestingly, we also
identiﬁed Ago2 as a GST-PINIT interactor from both brain homog-
enate and COS-7 cells. Because of the fundamental role of Ago2 and
the potential importance of its regulation by SUMOylation we
focused on Ago2 as a novel SUMO substrate. We validated the
interaction between GST-PINIT and Ago2 using GST pulldowns.
Lysates from COS-7 cells transfected with N-terminally myc-tagged
Ago2 were incubated with glutathione beads loaded with GST or
GST-PINIT. As expected GST-PINIT, but not GST alone, pulled down
myc-Ago2 (Fig. 1B). These data suggest that Ago2 may be a novel
SUMO substrate.3.2. Ago2 is SUMOylated in mammalian cells
We next transfected N2a neuroblastoma cells with myc-Ago2,
the SUMO conjugating enzyme Ubc9, and conjugatable or non-
conjugatable (lacking the C-terminal diglycine motif required for
conjugation) YFP-tagged SUMO1 and SUMO2. SUMOylated proteins
were enriched by pulldown with GFP-trap beads, followed by
western blotting for myc (Fig. 2A). Consistent with SUMO modiﬁ-
cation of Ago2, we detected a higher molecular weight form of
Ago2 only in the presence of conjugatable SUMO. Interestingly, in
the presence of conjugatable SUMO we also consistently observed
stronger binding of non-modiﬁed Ago2 to the GFP-trap beads
(compared to the non-conjugatable SUMO), suggesting Ago2 may
additionally interact non-covalently with another SUMOylated
protein.Fig. 1. Ago2 interacts with the PINIT domain of PIAS3. A) Schematic of the proposed
function of PIAS proteins in regulating SUMO modiﬁcation. PIAS proteins bind Ubc9
and SUMO, positioning them in an orientation conducive to SUMO transfer, but can
also directly contact substrates through the PINIT domain. B) Myc-Ago2 binds GST-
PIAS3-PINIT. Myc-Ago2 was transfected into COS-7 cells, and lysates subjected to GST
pulldownwith GST or GST-PIAS3-PINIT followed by western blotting for the myc-tag in
Ago2. The Ponceau staining reﬂects the amount of GST control or GST-PINIT used for
the pulldowns.3.3. Ago2 is SUMOylated primarily at K402
Analysis of the human Ago2 protein sequence using the
SUMOylation site prediction software SUMOsp revealed 5 potential
high-probability SUMO target lysines e K62, K65, K266, K402 and
K693 (Fig. 2B). We therefore mutated each of these lysines to
arginine in myc-Ago2, and examined whether these mutants could
be SUMOylated in mammalian cells. As previously, N2a cells were
transfected with myc-Ago2, FLAG-tagged Ubc9, and YFP-SUMO1
and YFP-SUMO2 and YFP-SUMO-modiﬁed species enriched using
GFP-trap beads. Ago2-SUMOylation was unaffected by mutation of
K62, 65, 266 or 693 to arginine, but was very strongly reduced upon
mutation of K402 (Fig. 2C), suggesting that Ago2 is primarily
modiﬁed by SUMO at K402, which lies within the SUMOylation
consensus sequence 401VKDE.
3.4. Ago2 is SUMOylated by both SUMO1 and SUMO2
Since the higher molecular weight form of Ago2 identiﬁed in
Fig. 2A and C could represent SUMO1 or SUMO2 modiﬁcation of
Ago2, we next determined which SUMO paralogues modify Ago2.
N2a cells were transfected with myc-Ago2 WT or K402R, FLAG-
Ubc9 and either YFP-SUMO1 or YFP-SUMO2 in either their con-
jugatable or non-conjugatable (DGG) forms. Proteins conjugated to
YFP-SUMO were isolated using GFP-trap beads and higher molec-
ular weight forms of Ago2 were visible with the conjugatable forms
of both SUMO1 and SUMO2, suggesting Ago2 can be modiﬁed by
both paralogues (Fig. 3A). Furthermore, mutation of K402
dramatically reduced SUMOylation, indicating that K402 is the
primary site ofmodiﬁcation by both SUMO1 and SUMO2.We noted,
however, that some residual modiﬁcation of Ago2 with SUMO1
remained in the K402 point mutant (Fig. 3A). To further conﬁrm
that the higher molecular weight band observed in these assays is
SUMOylated Ago2, we treated one set of pulldowns with the re-
combinant catalytic domain of the SUMO-speciﬁc deSUMOylating
enzyme SENP1. As expected, SENP1 reduced the higher molecular
weight band to a level similar to mutation of K402 (Fig. 3A). Taken
together, these data indicate that Ago2 can be modiﬁed by both
SUMO1 and SUMO2, primarily at K402.
3.5. Mutation of the SUMOylation consensus site at K402 ablates
Ago2 SUMOylation
Because some Ago2 SUMOylation persisted in the K402 mutant
we wondered if Ago2 is modiﬁed at other lysines when the
preferred K402 is no longer available. However, the observation
that mutation of the other high-probability lysines did not reduce
Ago2 SUMOylation (Fig. 2C) suggests that these sites are not
strongly recognised by the SUMOylation machinery. SUMOylation
within a consensus site proceeds via recognition of this motif by the
SUMO conjugating enzyme Ubc9. Intriguingly, however, Ubc9 can
still recognise a SUMOylation consensus motif in which the target
lysine has beenmutated to arginine [17]. Therefore, we investigated
if Ubc9 still recognises Ago2within the SUMOylation consensus site
after K402 has beenmutated, but now covalently modiﬁes adjacent
lysine residues. We generated a mutant in which the consensus
motif was changed from 401VKDE to 401AKAA (Ago2-3mutCS). We
then transfected myc-Ago2 WT, K402R or 3mutCS into N2a cells
with FLAG-Ubc9 and conjugatable or non-conjugatable SUMO1.
Interestingly, despite retaining lysine 402, mutation of the
SUMOylation consensus site in the 3mutCS mutant reduced
SUMOylation of Ago2 more profoundly than mutation of K402 to
arginine, strongly suggesting that the residual SUMOylation of the
K402R mutant is mediated through recruitment of Ubc9 via the
consensus sequence surrounding K402 (Fig. 3B).
Fig. 2. Ago2 is SUMOylated in mammalian cells, primarily at K402. A) Myc-Ago2 was transfected into N2a cells with FLAG-Ubc9 and either conjugatable (GG) or non-conjugatable
(DGG) forms of YFP-SUMO1 and YFP-SUMO2. SUMOylated proteins were enriched on GFP-trap beads followed by western blotting for myc. The putative Ago-SUMO band is
indicated by an arrow. B) Table demonstrating putative SUMOylation sites in human Ago2 as determined by the web-based SUMOylation prediction program SUMOsp. C) Mutation
of K402 to arginine largely abolishes Ago2 SUMOylation. N2a cells were transfected as in A) with wild-type or various point-mutants of myc-Ago2, followed by enrichment of
SUMOylated species on GFP-trap beads and western blotting for myc.
Fig. 3. Mutation of the SUMOylation consensus site in Ago2 abolishes SUMOylation. A) Myc-Ago2 can be modiﬁed at K402 by both SUMO1 and SUMO2. N2a cells were transfected
as indicated, and SUMOylated proteins enriched on GFP-trap beads followed by western blotting. For one set, after the pulldown and extensive washing, the beads were treated with
the recombinant catalytic domain of the SUMO-speciﬁc protease SENP1 to further conﬁrm the identity of the higher molecular weight species of Ago2 as Ago2-SUMO. B) Ablation of
the SUMOylation consensus site surrounding K402 reduces the residual SUMOylation observed upon mutation of K402 to alanine. Cells were transfected as indicated, followed by
enrichment of YFP-SUMOylated proteins on GFP-trap beads and western blotting.
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The best-characterised role of Ago2 is the processing of micro-
RNAs to mediate degradation of target mRNAs. We thereforeexamined the role of Ago2 SUMOylation on this process. Since Ago2
is solely responsible for the processing of siRNAs [23], we examined
siRNA efﬁciency as readout of Ago2 function. To exclude any con-
founding effect of endogenous Ago2, we performed these assays in
F. Josa-Prado et al. / Biochemical and Biophysical Research Communications 464 (2015) 1066e10711070Ago2 knockout MEFs. We transfected MEFs with renilla luciferase,
ﬁreﬂy luciferase and either a scrambled siRNA, or an siRNA tar-
geting renilla luciferase. Levels of renilla and ﬁreﬂy luciferase were
then measured with a luminometer, and renilla luciferase levels
normalised to ﬁreﬂy luciferase. Under control conditions, where
GFP was transfected instead of Ago2, the siRNA against renilla
luciferase had no effect (115.5% ± 16.4%), conﬁrming the require-
ment of Ago2 for siRNA activity in the knockout MEFs (Fig. 4A).
Expression of myc-Ago2WT dramatically reduced renilla luciferase
levels (13.1% ± 2.8%; Fig. 4B). Surprisingly, the Ago2 K402 mutant
was as efﬁcient as WT Ago2 in mediating knockdown of renilla
luciferase (21.8% ± 5.6%). However, knockdown of renilla luciferase
was signiﬁcantly attenuated (47.0% ± 8.6%) in the Ago2 3mutCS
mutant, in which the docking site for Ubc9 was ablated. Taken
together, these results suggest that SUMOylation of Ago2 may be
required for its full RNAi activity.
4. Discussion
Despite the fact that RNA interference is now well-established
as a fundamental gene regulatory mechanism in eukaryotic cells,
many key questions remain about how this pathway is regulated.
Here, we show that Ago2, the core catalytic component of the RNAi
pathway, is a substrate for SUMOylation in our ectopic expression
system. Ago2 was identiﬁed as an interactor of the PINIT domain of
PIAS3 and, in mammalian cell SUMOylation assays, is SUMOylated
by both SUMO1 and SUMO2.
Ago2 is primarily SUMOylated at K402, although some residual
SUMOylation of Ago2 occurs when this lysine is mutated to an
arginine. Importantly, this remaining SUMOylation was almost
completely abolished by mutation of the SUMOylation consensus
site surrounding K402. These results suggest that the consensus
motif represents the major binding site for the SUMO conjugating
enzyme Ubc9 and that, when lysine 402 is not available for modi-
ﬁcation, Ubc9 can insteadmodify nearby lysines. Indeed, analysis of
the structure of Ago2 reveals several lysines (K39, K52, K212 and
K739) that lie in close proximity to K402, and may represent
SUMOylation targets in the absence of K402 (Supp. Fig. 1). Impor-
tantly, disruption of Ubc9 recruitment by mutation of the
consensus site surrounding K402 site led to a signiﬁcant reduction
in the RNAi activity of Ago2, highlighting the potential role of
SUMOylation in regulating Ago2 function.
While thismanuscript was in preparation, work from the Dejean
lab has independently identiﬁed Ago2 as a substrate for SUMOy-
lation [20]. Consistent with our results, Sahin et al. (2014) identiﬁed
K402 as the major SUMOylation site. Moreover, similar to ourFig. 4. SUMOylation of Ago2 is required for correct siRNA activity. Ago2 knockout MEFs
were transfected with plasmids encoding ﬁreﬂy luciferase, renilla luciferase, and either
a scrambled siRNA or renilla luciferase siRNA along with GFP (A) or wild-type or
mutant Ago2 (B). 48 h post-transfection, cells were lysed and luciferase activity
quantiﬁed. Renilla luciferase levels were normalised to ﬁreﬂy luciferase (n ¼ 4;
** ¼ p < 0.01, *** ¼ p < 0.001).results, they also observed some residual SUMOylation upon mu-
tation of K402 to arginine and observed no effect of mutating K402
on the RNAi activity of Ago2. Importantly, however, we did observe
an effect of mutation of the SUMOylation consensus site sur-
rounding K402 on Ago2-dependent siRNA activity. While we
cannot exclude the possibility that the effect of the 3mutCS mutant
occurs independently from SUMOylation, our results indicate an
effect of Ago2 SUMOylation on the efﬁciency of siRNA-mediated
mRNA processing. Taken together, these data suggest that the re-
sidual SUMOylation of Ago2 observed for the K402R mutant is
sufﬁcient to maintain RNAi activity of Ago2. Preventing this resid-
ual SUMOylation by removing the consensus Ubc9 binding motif
reveals a requirement for Ago2 SUMOylation on RNAi activity
(Supp. Fig. 2). Sahin et al. (2014) further reported a role for Ago2
SUMOylation in protecting Ago2 from degradation. Mutation of
K402 to arginine, or depletion of Ubc9, increased the stability of
Ago2, suggesting that SUMOylation may play a multifaceted role in
Ago2 function and stability [7].
Exactly how SUMOylation of Ago2 regulates RNAi activity is
currently unclear. K402 lies close to the surface in Ago2 that me-
diates binding to Dicer, suggesting that mutation of the SUMOyla-
tion consensus sequence or addition of a ~10 kDa SUMO protein to
this site may regulate the ability of Ago2 to undergo RNA loading by
Dicer. Furthermore, phosphorylation of Ago2 at Y393, nine residues
upstream of the SUMOylated lysine, has been reported to occur
during hypoxia and reduce binding to Dicer [6]. Given the growing
number of examples of cross-talk between phosphorylation and
SUMOylation pathways, it seems possible that phosphorylation of
Y393 promotes Ubc9 recruitment to the consensus site surround-
ing K402 to enhance Ago2 SUMOylation and regulate RISC complex
assembly under conditions of hypoxia. Consistent with this, Sahin
et al. (2014) observed reduced SUMOylation of Ago2 uponmutation
of Y393 to alanine [20]. Indeed, this model is particularly attractive
given the massive increase in protein SUMOylation upon hypoxia
induction, and suggests one of these target proteins may be Ago2.
In summary, we have identiﬁed Ago2 as a novel substrate for
SUMOylation and demonstrate a potential role for Ago2 SUMOy-
lation in regulating its RNAi activity. These data add to the ever-
growing diversity of cellular processes known to be regulated by
SUMOylation, and enhance our knowledge of the complex regula-
tory mechanisms that ﬁne tune Ago2-mediated control of gene
expression in eukaryotic cells.
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